Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 387 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Grandma Saves Her Money To Put Up A Billboard For Everyone... June 14, 2019 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma June 11, 2024 Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 Load more HOT NEWS Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... Happy 29th Birthday OncoLink!
